Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07457411

Implementation Outcomes and Cost-effectiveness of Developmental Monitoring for Children Exposed to HIV

The goal of this study is to learn about how to best carry out neurodevelopmental screening methods (tests to see if a young child can use support with brain development) in routine clinic visits in Botswana and Kenya among children age 16-24 months old.

The main questions it aims to answer are: 1. when used in routine clinic visits by healthcare workers, how many children are able to get screened; 2. are the screening tools appropriate and how can they best be used; 3. how much time and money does it take to use the screening methods?

The investigators will compare two screening methods chosen by healthcare workers at the beginning of the study. Children will undergo a brief test of their brain development to see if they need further evaluation and support. Caregivers will be asked to complete a short survey to see what they thought of the screening test. Healthcare workers will complete brief surveys and interviews to see what they thought of carrying out the screening tests and how use of the screening tests can be improved in their clinics.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

16 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The two neurodevelopmental screening methods identified by healthcare workers at the beginning of the study may include the Global Scale for Early Development (GSED), a new validated risk score, Developmental Screen Questionnaire (DSQ), or another appropriate method identified by in-country experts. These screening tools will be administered to children age 16-24 months who come to the clinic for routine wellness check ups and will last about 5-20 minutes depending on the tool. The pilot tests of these screening method will take part at 5 clinics in Botswana and 5 clinics in Kenya, for 5 months per tool. The research study will collect information on whether the screening test was done, how long it took, the outcome of the screening test for each child, and the child's gender and age. No identifying information will be collected about the child.

At the end of the clinic visit, caregivers will be provided with an information sheet about the study and whether and how to get any follow up evaluation or support for their child. Healthcare workers will be trained on how to administer the tool and provide follow up support to children and caregivers. Caregivers will also be asked to complete a brief survey about whether they found the screening method to be acceptable and if they were satisfied with clinic services.

Healthcare workers will be trained on how to administer the screening tool to children. They will ask the caregiver to carry a time card throughout the visit so the study can measure how much time the screening tool took to administer in a real world setting. Healthcare workers will administer the tool, including recording information from the child's medical records to understand neurodevelopmental risk. Every two months, healthcare workers will be asked to complete a brief survey to indicate if the tool is usable, acceptable, and feasible. At the end of the five month pilot test of a tool, healthcare workers and health records officers will be asked to take part in an individual interview to better understand how their experience was using the tool, barriers to using the tool, and how the tool can be better implemented in their clinic. They will get a small amount of money as compensation for time and effort of participating in surveys and interviews.

This study will provide critical, concrete guidance to policymakers to inform early, context-specific policies for implementing neurodevelopmental screening, diagnostics, and therapeutics within programmatic settings with high HIV prevalence.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthcare workers (HCW): age 18 years or older
  • HCW: working at one of the clinics engaged in the study caring for children at routine clinic appointments
  • Children: age 16-24 months
  • Children: attending routine clinic appointment at one of the clinics engaged in the study
  • Caregivers: age 18 years or older
  • Caregivers: caregiver of child eligible for participation

Exclusion criteria

  • None

Treatment and study plan

Neurodevelopmental screening

Other

The two neurodevelopmental screening methods tested may include the Global Scale for Early Development (GSED), a new validated risk score, Developmental Screen Questionnaire (DSQ), or another appropriate method identified by in-country experts.

Primary outcomes

  1. Screening method coverage

    Time frame: Over each of two 5-month pilot tests

    Number of eligible children who receive the screening method at their routine clinic appointment compared to number of total eligible children who have a routine clinic appointment

  2. Implementation outcomes for screening methods: Acceptability

    Time frame: Over each of two 5-month pilot tests

    Acceptability questionnaire

  3. Cost of using screening method

    Time frame: Over each of two 5-month pilot tests

    Costing data from budgets, records, time-and-motion direct observation, time-and-motion clinic visit time cards

  4. Implementation outcomes for screening methods: Feasibility

    Time frame: Over each of two 5-month pilot tests

    Feasibility questionnaire

  5. Implementation outcomes for screening methods: Fidelity

    Time frame: Over each of two 5-month pilot tests

    Questionnaires on fidelity of screening method

Secondary outcomes

  1. Risk score

    Time frame: At each routine clinic appointment, over each of two 5-month pilot tests

    Results from neurodevelopmental risk score; range from 0-1 as a decimal; higher numbers indicate higher risk of poor neurodevelopmental outcome

  2. GSED screening tool

    Time frame: At each routine clinic appointment, over each of two 5-month pilot tests

    Results from the Global Scales for Early Development; represented as a Developmental score (D-score), which is a z-score standardized to the child's age. Positive numbers indicate better than typical development for a child's age; negative numbers indicate poorer than typical development for a child's age

  3. Caregiver satisfaction

    Time frame: Day 1 (at routine clinic visit)

    Questionnaire on caregiver satisfaction with experience of screening method

Study contacts

Contact information is provided by the study sponsor or research team.

Anjuli D Wagner, PhD, MPH

CONTACT

[email protected]

978-460-2331

Katy Sharrock, MS

CONTACT

[email protected]

8472350168

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Registry information

Acronym: IMPLEMENT

Important dates

Study start
2027
Primary completion
2028
Study completion
2028
First posted
Mar 9, 2026
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.